Fundz

Lexicon Pharmaceuticals

The Woodlands, TX · Healthcare, Health Care · 110 employees

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the dis

Funding history

  • Funding Round — $55.7M — Feb 2026
  • Funding Round — $75.0M — Nov 2025
  • Funding Round — $72.2M — Jun 2023
  • Funding Round — $42.9M — Aug 2022
  • Funding Round — $10.5M — Mar 2017

Recent signals

  • Mar 05, 2026: SEC 8-K (2.02): On March 5, 2026, Lexicon Pharmaceuticals, Inc. reported its financial results for the quarter and year ended December 31, 2025. The press release, attached as Exhibit 99.1, likely contains important financial metrics and performance indicators that are relevant for shareholders and stakeholders. This release is significant as it provides insight into the company's financial health and operational performance in the preceding fiscal period, which can influence investment decisions and the company's market perception.
  • Feb 17, 2026: Raised $55.7M
  • Nov 06, 2025: Raised $75.0M
  • Nov 06, 2025: SEC 8-K (1.01): On November 6, 2025, Lexicon Pharmaceuticals, Inc. entered into a material definitive agreement concerning its Open Market Sale Agreement with Jefferies LLC. This agreement allows Lexicon to offer and sell up to $75,000,000 of its common stock through Jefferies. The agreement was originally dated December 29, 2023, and a prospectus supplement related to this offering was filed with the SEC on the same date. No sales have been made under this agreement as of November 6, 2025. The arrangement signifies a strategic initiative for Lexicon to raise capital for its business operations.
  • Mar 29, 2025: Lexicon Pharmaceuticals licenses drug candidate LX9851 to Novo Nordisk in billion-dollar deal
  • Feb 18, 2025: Launched Lexicon Pharmaceuticals announces the publication of a research paper on sotagliflozin, highlighting its efficacy in reducing major adverse cardiovascular events.
  • Jun 20, 2023: Raised $72.2M
  • Aug 03, 2022: Raised $42.9M

See plans & pricing → Track Lexicon Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.